Holen Sie sich die Stockscreener-App
4.60
8.73%
-0.44
Handel nachbörslich:
4.65
0.05
+1.09%
Schlusskurs vom Vortag:
$5.04
Offen:
$5.02
24-Stunden-Volumen:
1.41M
Relative Volume:
1.55
Marktkapitalisierung:
$144.53M
Einnahmen:
$19.09M
Nettoeinkommen (Verlust:
$-82.13M
KGV:
-1.6413
EPS:
-2.8026
Netto-Cashflow:
$-70.00M
1W Leistung:
-11.88%
1M Leistung:
-12.05%
6M Leistung:
-64.29%
1J Leistung:
-88.31%
1-Tages-Spanne:
$4.535
$5.25
1-Wochen-Bereich:
$4.535
$6.74
52-Wochen-Spanne:
$4.535
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Firmenname
Lenz Therapeutics Inc
Sektor
Branche
Telefon
858-925-7000
Adresse
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
4.60 | 158.36M | 19.09M | -82.13M | -70.00M | -2.8026 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-03-18 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Eingeleitet | Raymond James | Outperform |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2024-04-15 | Eingeleitet | William Blair | Outperform |
| 2024-04-10 | Eingeleitet | Citigroup | Buy |
| 2024-03-27 | Eingeleitet | Piper Sandler | Overweight |
| 2023-02-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | Herabstufung | Cowen | Outperform → Market Perform |
| 2023-01-25 | Herabstufung | BTIG Research | Buy → Neutral |
| 2023-01-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-06 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-04-14 | Eingeleitet | BTIG Research | Buy |
| 2022-03-22 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-07-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lenz Therapeutics Inc Aktie (LENZ) Neueste Nachrichten
Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ) - Seeking Alpha
BofA downgrades Lenz Therapeutics stock rating on slow launch By Investing.com - Investing.com Australia
BofA downgrades Lenz Therapeutics stock rating on slow launch - Investing.com
Why is LENZ Therapeutics stock rallying today? - Investing.com
Why is LENZ Therapeutics stock rallying today? By Investing.com - Investing.com Canada
LENZ Therapeutics earnings beat by $0.05, revenue topped estimates - Investing.com Canada
LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $29.86, Implies 473% Upside - TradingView
LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ... By GuruFocus - Investing.com Canada
Lenz Therapeutics Posts Q2 Revenue Fueled by VIZZ Sales and License Agreements - VisionMonday.com
LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LENZ Therapeutics Q2 Earnings Call Highlights - TradingView
LENZ Therapeutics (NASDAQ:LENZ) Issues Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
LENZ Therapeutics Q2 Results: Sales surge 131% vs estimates - scanx.trade
LENZ Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
LENZ: July prescriptions surged 45%+ after telehealth and TV launches, with strong patient persistence - TradingView
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: LENZ Therapeutics tops Q2 2026 forecasts as sales jump - Investing.com
Transcript : LENZ Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com
LENZ Therapeutics (LENZ) grows VIZZ sales but posts $31.9M Q2 loss - Stock Titan
LENZ THERAPEUTICS ($LENZ) Releases Q2 2026 Earnings, Stock Rises - Quiver Quantitative
LENZ Therapeutics Q2 revenue rises on VIZZ sales - TradingView
LENZ Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - ir.lenz-tx.com
Over 60% of LENZ’s VIZZ ePharmacy Patients Bought Multiple Packs - Stock Titan
LENZ Therapeutics Inc (NASDAQ: LENZ) Share Price, LENZ Stock News, LENZ Share Price & Updates - Kalkine
LENZ Therapeutics Inc (LENZ) Q2 2026 Earnings Report Preview: Wh - GuruFocus
LENZ Therapeutics, Inc. (LENZ) Stock Analysis: A Biotech With A Potential 513% Upside - DirectorsTalk Interviews
LENZ Therapeutics Inc (LENZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026 - marketscreener.com
LENZ|LENZ Therapeutics Inc|Price:5.695|Chg%:+0.215 - TradingKey
LENZ Therapeutics Inc (LENZ) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LENZ Therapeutics Inc (LENZ) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
LENZ Therapeutics Inc (LENZ) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
LENZ Therapeutics, Inc. Revenue Breakdown – NASDAQ:LENZ - TradingView
LENZ Therapeutics Inc (LENZ) Cash Flow - TradingKey
TradingKey - TradingKey
LENZ Therapeutics Inc (LENZ) Institutional Confidence - TradingKey
LENZ Therapeutics Inc expected to post a loss of $1.07 a shareEarnings Preview - TradingView
LENZ Therapeutics Inc (LENZ) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
LENZ|LENZ Therapeutics Inc|Price:5.750|Chg%:+0.051 - TradingKey
LENZ Therapeutics (LENZ) Q1 2026 earnings summary - Quartr
LENZ Therapeutics (LENZ) 2024 Cantor Fitzgerald Global Healthcare Conference Summary - Quartr
LENZ Therapeutics Inc (LENZ) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
LENZ Therapeutics (LENZ) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Earnings preview: LENZ Therapeutics, Inc. (LENZ) Q2 earnings expected to decline - MSN
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline - Yahoo Finance
LENZ Therapeutics (LENZ) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
LENZ Therapeutics (LENZ) Projected to Post Earnings on Wednesday - MarketBeat
LENZ Therapeutics (LENZ) Leerink Global Healthcare Conference 2026 Summary - Quartr
LENZ Therapeutics (LENZ) Proxy filing Summary - Quartr
Finanzdaten der Lenz Therapeutics Inc-Aktie (LENZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.03%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):